News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Astellas Pharma Inc. Withdraws Japan Filing for Darexaban, Looks for Partners
February 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Astellas Pharma has pulled its filing in Japan for its oral Factor Xa inhibitor darexaban after regulators said they needed to see more data.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Rare disease
UniQure Eyes Phase 3 for Huntington’s Gene Therapy Despite Makary’s Apparent Criticism
March 2, 2026
·
3 min read
·
Heather McKenzie
Approvals
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug
March 2, 2026
·
2 min read
·
Tristan Manalac
CDC
RFK Jr. Appoints 2 New Advisors to CDC Vaccine Panel Ahead of March Meeting
March 2, 2026
·
2 min read
·
Tristan Manalac
Regulatory
FDA Action Alert: BMS, GSK, Aldeyra and More
March 2, 2026
·
4 min read
·
Tristan Manalac
